The clinical trial of eloralintide for obesity treatment will start next month.

On November 12th, Lilly announced positive results from the phase 2 clinical study of eloralintide, a selective glucagon-like peptide-1 receptor agonist being investigated for once-weekly dosing. The study evaluated the safety and efficacy of eloralintide in 263 overweight adults without type 2 diabetes or with at least one weight-related comorbidity. At week 48, all dose groups of eloralintide met the primary endpoint, with average weight loss ranging from 9.5% to 20.1%, superior to the placebo group's average of 0.4% loss. Based on these trial results, Lilly will initiate enrollment in a phase 3 clinical study for the treatment of obesity with eloralintide next month.